ET-01 in Subjects With Lateral Canthal Lines, LCL-209

Completed · Phase 2

Conditions studied: Lateral Canthal Lines, LCL, Crow's Feet

In brief

This study tests an investigational drug formulation called ET-01, botulinum toxin, Type A, topical, in lateral canthal lines (LCL).

Key facts

Study ID

NCT03912805

Run by

Eirion Therapeutics Inc.

People needed

38

Starts

2019-02-27

Expected to finish

2019-10-04

Last updated by the study team

2022-07-28

Who can join

Age: 25 and older, up to 65. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• females 25 - 65 years of age
• minimal to moderate Crow's Feet wrinkles at rest
• moderate to severe Crow's Feet on contraction
• adequate vision to assess facial wrinkles in a mirror
• willingness to refrain from products affecting skin remodeling
• female subjects must be not pregnant and non-lactating
• subjects should be in good general health

You may not qualify if…

• history of adverse reactions to any prior botulinum toxin treatments
• history of vaccination or non-response to any prior botulinum toxin treatments
• botulinum toxin treatment in the prior 6 months
• present or history of neuromuscular disease, eyelid ptosis, muscle weakness, paralysis, or "dry eye"
• history of peri-ocular surgery, brow lift or related procedures
• procedures affecting the lateral canthal region in the prior 12 months
• application of topical prescription medication to the treatment area
• female subjects who are pregnant or are nursing a child

Where it is running

• Synexis, Inc. — Pinellas Park, Florida, United States
• Yardley Dermatology Associates — Yardley, Pennsylvania, United States
• Virginia Clinical Research, Inc. — Norfolk, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.